Maintenance fees coming due
9 maintenance fees come due in the 12 months from Nov 17, 2026, the next on Jan 11, 2027. Unpaid by Jul 12, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,697,688 | ANTI-CD25 for Tumour Specific Cell Depletion In force Fee due Jan 11, 2027 Lapses if unpaid Jul 12, 2027 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics Ltd. | In force | Jan 11, 2027 | Jul 12, 2027 | High confidence | |
| US 11,787,866 | ANTI-CD25 Antibody Agents In force Fee due Apr 17, 2027 Lapses if unpaid Oct 18, 2027 · High confidence | Tusk Therapeutics, Ltd. | In force | Apr 17, 2027 | Oct 18, 2027 | High confidence | |
| US 11,802,160 | ANTI-CD25 Antibody Agents In force Fee due Apr 30, 2027 Lapses if unpaid Nov 1, 2027 · Low confidence | Tusk Therapeutics Ltd. | In force | Apr 30, 2027 | Nov 1, 2027 | Low confidence | |
| US 11,802,161 | ANTI-CD25 for Tumour Specific Cell Depletion In force Fee due Apr 30, 2027 Lapses if unpaid Nov 1, 2027 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics Ltd. | In force | Apr 30, 2027 | Nov 1, 2027 | High confidence | |
| US 11,814,434 | ANTI-CD25 for Tumour Specific Cell Depletion In force Fee due May 14, 2027 Lapses if unpaid Nov 15, 2027 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics Ltd. | In force | May 14, 2027 | Nov 15, 2027 | High confidence | |
| US 11,851,494 | ANTI-CD25 for Tumour Specific Cell Depletion In force Fee due Jun 26, 2027 Lapses if unpaid Dec 27, 2027 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics Ltd. | In force | Jun 26, 2027 | Dec 27, 2027 | High confidence | |
| US 11,873,341 | ANTI-CD25 for Tumour Specific Cell Depletion In force Fee due Jul 16, 2027 Lapses if unpaid Jan 18, 2028 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics Ltd. | In force | Jul 16, 2027 | Jan 18, 2028 | High confidence | |
| US 11,879,014 | A Method of Treating Cancer or Depleting Regulatory T Cells in a Subject by Administering a Human IGG1 ANTI-CD25 Antibody In force Fee due Jul 23, 2027 Lapses if unpaid Jan 24, 2028 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics Ltd. | In force | Jul 23, 2027 | Jan 24, 2028 | High confidence | |
| US 11,919,960 | ANTI-CD25 Antibody Agents In force Fee due Sep 5, 2027 Lapses if unpaid Mar 6, 2028 · High confidence | Cancer Research Technology Limited and Tusk Therapeutics LTC. | In force | Sep 5, 2027 | Mar 6, 2028 | High confidence |
9 of 9 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.